Skip to main content
Journal cover image

Antibiotics and Surgical Site Infection in Expander-Based Breast Reconstruction Trial (ASSERT).

Publication ,  Journal Article
Kaur, S; Gastman, B; Broderick, KP; Momoh, AO; Phillips, BT; Schwarz, G; Hanson, SE; Hespe, GE; Cooney, CM; Sommers, K; Leu, C-S; Rohde, CH ...
Published in: Ann Surg Oncol
October 14, 2025

BACKGROUND: The use of prophylactic antibiotics following postmastectomy tissue expander breast reconstruction (TE-BR) varies widely. The Centers for Disease Control and Prevention (CDC) recommends a single preoperative antibiotic dose for clean and clean-contaminated procedures. This multi-institutional, prospective, randomized controlled trial (RCT) examined whether the CDC-recommended single preoperative dose (SPD) of antibiotics is not inferior to an additional week of postoperative (WPO) prophylactic antibiotics in preventing surgical site infection (SSI) in immediate TE-BR following mastectomy. METHODS: Women aged ≥ 18 years undergoing immediate TE-BR were randomized to SPD or WPO groups. The primary outcome was SSI by CDC guidelines within 30 days of surgery. The study used a noninferiority trial design to examine whether the test product (single preoperative dose (SPD)) was not worse than the comparator (1 week of postoperative (WPO) prophylactic antibiotics) by more than a set noninferiority margin of 6%. RESULTS: In total, five participating centers screened 499 women; 235 were enrolled. A total of 102 patients were randomized to the SPD arm and 112 to the WPO arm, with 21 patients withdrawn. The SSI rate in the SPD arm was 17% as compared with 11% in WPO arm, which is within the noninferiority margin set for this study but not significantly noninferior (p = 0.496). The rate of unplanned TE removal for infection, hospitalization rate, and return to OR rate within 30 days of surgery were comparable between the two groups. CONCLUSIONS: This multi-institutional RCT did not definitively demonstrate that a single preoperative dose of antibiotics is not inferior to a 7-day postoperative antibiotic regimen in preventing SSI in immediate TE-BR; there was also no evidence to support that the 7-day regimen was significantly better. As this represents one of the largest multi-institutional study of its kind, these results have practice-management considerations.

Duke Scholars

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

October 14, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kaur, S., Gastman, B., Broderick, K. P., Momoh, A. O., Phillips, B. T., Schwarz, G., … ASSERT Group. (2025). Antibiotics and Surgical Site Infection in Expander-Based Breast Reconstruction Trial (ASSERT). Ann Surg Oncol. https://doi.org/10.1245/s10434-025-18472-6
Kaur, Surinder, Brian Gastman, Kristen P. Broderick, Adeyiza O. Momoh, Brett T. Phillips, Graham Schwarz, Summer E. Hanson, et al. “Antibiotics and Surgical Site Infection in Expander-Based Breast Reconstruction Trial (ASSERT).Ann Surg Oncol, October 14, 2025. https://doi.org/10.1245/s10434-025-18472-6.
Kaur S, Gastman B, Broderick KP, Momoh AO, Phillips BT, Schwarz G, et al. Antibiotics and Surgical Site Infection in Expander-Based Breast Reconstruction Trial (ASSERT). Ann Surg Oncol. 2025 Oct 14;
Kaur, Surinder, et al. “Antibiotics and Surgical Site Infection in Expander-Based Breast Reconstruction Trial (ASSERT).Ann Surg Oncol, Oct. 2025. Pubmed, doi:10.1245/s10434-025-18472-6.
Kaur S, Gastman B, Broderick KP, Momoh AO, Phillips BT, Schwarz G, Hanson SE, Hespe GE, Cooney CM, Sommers K, Leu C-S, Rohde CH, ASSERT Group. Antibiotics and Surgical Site Infection in Expander-Based Breast Reconstruction Trial (ASSERT). Ann Surg Oncol. 2025 Oct 14;
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

October 14, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis